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Abstract
Background: Effects of roflumilast on lung function, symptoms, acute exacerbation and adverse events in patients
with chronic obstructive pulmonary disease (COPD) are controversial. We aimed to further clarify the efficacy and
safety of roflumilast in treatment of moderate-to-severe COPD.
Methods: From 1946 to November 2015, we searched the Pubmed, Embase, Medline, Cochrane Central Register of
Controlled Trials, ISI Web of Science and American College of Physician using “roflumilast” and “chronic obstructive
pulmonary disease” or “COPD”. Randomized controlled trials that reported forced expiratory volume in one second
(FEV1), forced vital capacity (FVC), transition dyspnea index (TDI), St George’s Respiratory Questionnaire (SGRQ), and
incidence of COPD exacerbations and adverse events were eligible. We conducted the heterogeneities test and
sensitivity analysis, and random-effects or fixed-effects model was applied to calculate risk ratio (RR) and mean
difference (MD) for dichotomous and continuous data respectively. Cochrane systematic review software, Review
Manager (RevMan), was used to test the hypothesis by Mann-Whitney U-test.
Results: Thirteen trials with a total of 14,563 patients were pooled in our final studies. Except for SGRQ (I2 = 63 %,
χ2 = 1.71, P = 0.07) and adverse events (I2 = 94 %, χ2 = 0.03, P < 0.001), we did not find statistical heterogeneity in
outcome measures. The pooled MD of pre- and post-bronchodilator FEV1 was 54.60 (95 % confidence interval (CI)
46.02 ~ 63.18) and 57.86 (95 % CI 49.80 ~ 65.91), and both showed significant improvement in patients with roflumilast
(z = 12.47, P <0.001; z = 14.07, P < 0.001), so did in FVC (MD 90.37, 95 % CI 73.95 ~ 106.78, z = 10.79, P < 0.001).
Significant alleviation of TDI (MD 0.30, 95 % CI 0.14 ~ 0.46, z = 3.67, P < 0.001) and decrease of acute exacerbation (RR 0.86,
95 % CI 0.81 ~ 0.91, z= 5.54, P < 0.001) were also identified in treatment of roflumilast, but without significant difference in
SGRQ (MD −1.30, 95 % CI −3.16 ~ 0.56, z = 1.37, P = 0.17). Moreover, roflumilast significantly increased the incidence of
adverse events compared with placebo (RR 1.31, 95 % CI 1.16 ~ 1.47, z = 4.32, P < 0.001).
Conclusions: Roflumilast can be considered as an alternative therapy in selective patients with moderate-to-severe COPD.
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Background
Chronic obstructive pulmonary disease (COPD), a com-
mon disease with a prevalence reported to be 7.8 to
19.7 %, is characterized by persistent and progressive air-
flow limitation as well as frequent exacerbations [1, 2].
Global Burden of Disease (GBD) Study projected that
COPD will become the third leading cause of death world-
wide by 2020, and it was estimated as the direct under-
lying cause of 7.8 % of all deaths and 27 % of deaths
related with smoking [3, 4].
Acute exacerbation of COPD is defined as respiratory
symptoms deterioration and medication alteration, and
it has been demonstrated to be associated with detri-
ment of quality of life, decline of lung function and in-
crease of mortality [1, 5–7]. Hurst and his colleagues
analyzed 2138 patients with COPD, and they found a
trend of more exacerbations as the severity of COPD in-
creased, that was 22, 33 and 47 % in stage 2 (moderate),
stage 3 (severe) and stage 4 (very severe), respectively
[8]. Therefore, effective treatment and management in pa-
tients with moderate-to-severe COPD is paramount to de-
crease exacerbations, and improve lung function, quality
of life and clinical outcomes.
Phosphodiesterase-4 (PDE4) is a vital enzyme in the me-
tabolism of cyclic adenosine monophosphate (cAMP) and
inhibition of PDE4 can inactivate immune and inflamma-
tory cells via increase cAMP [9]. It is recommended by
the Global Initiative for Chronic Obstructive Lung Disease
(GLOD) guideline that a combination of PDE4 inhibitor
and long-acting bronchodilator can be considered as an
alternative treatment in patients with severe COPD due to
the effective improvement of lung functions [1]. Roflumi-
last is a novel selective inhibitor of PDE4, which functions
mainly by its active metabolite, roflumilast N-oxide, via
the conversion by cytochrome P450 (CYP) 3A4 and 1A2
isozymes [10]. Rabe and his colleagues conducted a ran-
domized controlled trial (RCT) in 1157 patients with
moderate-to-severe COPD, and they found that roflumi-
last could significantly improve post-bronchodilator
forced expiratory volume in one second (FEV1) (0.097 ±
0.018, P < 0.0001) and post-bronchodilator forced vital
capacity (FVC) (0.114 ± 0.031, P = 0.0002), and decrease
incidence of acute exacerbations (28 % vs. 35 %, P =
0.0114) compared with placebo [11], which were further
demonstrated by a subsequent meta-analysis of seven
trials with 9675 patients but without improving health-
related quality of life by St George’s Respiratory Ques-
tionnaire (SGRQ) (mean difference (MD) −0.70, 95 %
confidence interval (CI) −2.65 ~ 1.26, P = 0.49) or de-
creasing mortality rate (risk ratio (RR) 0.90, 95 % CI
0.63 ~ 1.29, P = 0.56) [12].
However, Fabbri and his colleagues randomly assigned
743 patients with moderate-to-severe COPD into roflu-
milast plus tiotropium and tiotropium groups and they
reported a significant improvement in Shortness of Breath
Questionnaire (SOBQ) (MD −2.6, 95 % CI −4.5 ~ −0.8, P =
0.0051) in roflumilast plus tiotropium [13]. Moreover, a
recent placebo-controlled randomized study, which in-
vestigated the additional treatment of roflumilast in
moderate-to-severe COPD with chronic bronchitis, did
not reveal any significant changes in lung function,
quality of life, or exercise tolerance between rolumilast
and placebo [14]. Therefore, the accurate roles of roflu-
milast in the treatment of patients with COPD still re-
main controversial.
In this study, we conducted a meta-analysis of all pub-
lished RCTs with the aim of updating and further clari-
fying the efficacy and safety of roflumilast in patients
with COPD.
Methods
Our study protocol was approved by the Institutional
Ethical Committee for Clinical and Biomedical Re-
search of West China Hospital (Sichuan, China), so did
in each enrolled trial by the corresponding institutional
review board. All participants provided written in-
formed consent.
Search strategies
From 1946 to November 2015, a comprehensive com-
puter search was conducted in Pubmed, Embase, Med-
line, Cochrane Central Register of Controlled Trials
(CENTRAL), ISI Web of Science and American College
of Physician (ACP) using the keywords of “roflumilast”
and “chronic obstructive pulmonary disease” or “COPD”
with limitation in the publication type of RCTs but not
in the publication language. We reviewed the references
listed in each identified article and manually searched
the related articles to identify all eligible studies and
minimize the potential publication bias.
Inclusion and exclusion criteria
Eligible clinical trials were defined based on the following
criteria: 1) study design was RCT; 2) moderate-to-severe
COPD was diagnosed by physicians according to the
guidelines released by GOLD with a post-bronchodilator
FEV1 between 30 and 80 % [1]; 3) age was more than
40 years old and smoking history was more than 10 pack-
years; and 4) intervention treatment was oral roflumilast
with a dose of 500ug and a frequency of once daily, but re-
gardless of administration durations. We did not enroll
trials that were retrospective, observational, cohort or case
control studies.
Outcome measures
Outcome measures consisted of efficacy assessment and
safety evaluation, which included: 1) change of lung func-
tions from baseline, such as pre-bronchodilator FEV1 and
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post-bronchodilator FEV1, FVC, force expiratory volume
in six seconds (FEV6) and forced expiratory flow between
25 and 75 % of the vital capacity (FEF25-75); 2) health-
related quality of life such as investigator-administered
transition dyspnea index (TDI) and SGRQ, and 3) inci-
dence of COPD exacerbations and adverse events.
Study selection
Two independent investigators performed the study se-
lection in two phases. Firstly, they discarded duplicated
and non-randomized controlled studies by screening ti-
tles and abstracts. Secondly, eligible studies were ex-
tracted by reviewing full texts in accordance with the
previously designed study inclusion criteria. Any dis-
agreement was solved by mutual consensus in the pres-
ence of a third investigator.
Data extraction
Independently, two data collectors extracted and recorded
desirable information of each enrolled study in a standard
form recommended by Cochrane [15], which consisted of
authors, publication year, registration series, study design,
participants and population, demographic characteristics
(age, gender, etc.), baseline characteristics (FEV1/FVC,
post-bronchodilator FEV1, post-bronchodilator FEV, etc.),
details of intervention treatment (dose, frequency, routine,
and duration), follow-up period, and outcome measures
and study results. For any missing data information, corre-
sponding authors were contacted by email to request the
full original data. Different opinions between the two col-
lectors were determined by reaching a consensus or con-
sulting a third investigator.
Quality assessment
For the assessment of risk of bias in estimating the study
outcomes, we used the Cochrane risk of bias tool [15].
Each study was assessed for: 1) random sequence gener-
ation (selection bias); 2) allocation concealment (selection
bias); 3) blinding of participants and personnel (perform-
ance bias); 4) blinding of related outcomes assessment
(detection bias); 5) incomplete outcome data (attrition
bias); 6) selective reporting (reporting bias); and 7) other
biases. Two investigators conducted the quality assess-
ment for the study methodology, independently and in
duplicate. Any divergence was resolved by mutual consen-
sus in the presence of a third investigator.
Statistical analysis
Statistical analysis of our study was accomplished by an
independent statistician using Cochrane systematic review
software Review Manager (RevMan; Version 5.3.5., The
Nordic Cochrane Centre, The Cochrane Collaboration,
Copenhagen, 2014). We used Mann-Whitney U-test to
verify hypothesis and rendered statistical significance as z-
value and P-value < 0.05, and the results were displayed in
Forest plots.
Continuous variables were reported as mean and stand-
ard derivation (SD), while dichotomous variables were
shown as frequency and proportion. An initial test for
clinical, methodological and statistical heterogeneities was
conducted, and we used the χ2 test with P < 0.1 and I2 >
50 % to indicate significance. We also performed the sen-
sitivity analysis to substitute alternative decisions or
ranges of values for decisions that were arbitrary or un-
clear, and tested the publication biases by Funnel plot.
Random-effects model was applied in the presence of
statistical heterogeneity; otherwise fixed-effects model was
used. For continuous data we calculated MD and 95 % CI,
while for dichotomous data we calculated RR and 95 %
CI. Furthermore, in terms of pre- and post-bronchodilator
FEV1, incidence of COPD exacerbation and adverse
events, we separately conducted sub-analysis at different
follow-up time points.
Results
Initially 120 records were identified, of which 118 were
extracted from electronic databases and 2 were extracted
from reference lists review. (Fig. 1) By screening the ti-
tles and abstracts, 99 studies were discarded for duplica-
tion (n = 52), not RCTs (n = 40), patients without COPD
(n = 6), and intervention treatment without roflumilast
(n = 1). We searched the full-text articles for the
remaining 21 studies, and eventually 13 trials [11, 13, 14,
16–25] were enrolled in our final analysis due to 5 stud-
ies not reporting eligible outcomes and 3 studies being
retrospective studies.
Study description
All 13 studies enrolled patients with severe COPD, but 2
studies [16, 17] also included mild COPD, 7 studies [11,
13, 14, 16, 17, 20, 23] included moderate COPD, and 6
studies [18, 19, 21, 22, 24, 25] included very severe COPD.
Except for one study [13] administering roflumilast plus
salmeterol or tiotropium as intervention treatment and
placebo plus salmeterol or tiotropium as control, all studies
compared roflumilast with placebo. Treatment duration
and follow-up period were not identical in different studies
with 2 studies [20, 23] for 12 weeks, 1 study [14] for
14 weeks, 4 studies [11, 13, 17, 24] for 24 weeks, 1 study
[16] for 26 weeks, and 5 studies [18, 19, 21, 22, 25] for
52 weeks. In terms of the outcome measures, 11 studies
[11, 13, 14, 16–21, 23, 24] reported change of pre-
bronchodilator FEV1, 10 studies [11, 13, 14, 18–21, 23–25]
reported change of post-bronchodilator FEV1, 8 studies
[11, 13, 14, 18–20, 24, 25] provided change of post-
bronchodilator FVC, 3 studies [11, 18, 20] provided change
of post-bronchodilator FEV6, 5 studies [11, 18–20, 23] pro-
vided change of post-bronchodilator FEF25-75, 4 studies
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[13, 19, 23, 24] presented data of TDI change, 4 studies
[11, 13, 18, 21] presented data of SGRQ change, 10 studies
[11, 13, 18–25] showed incidence of COPD exacerbation,
and 10 studies [11, 13, 14, 18–21, 23–25] showed incidence
of adverse events. Details of patients’ characteristics,
intervention strategies, and outcomes were summarized
in Tables 1 and 2.
A total of 14,563 patients with COPD were pooled
from all the included trials in our final meta-analysis,
among which 7,398 patients were assigned to receive
roflumilast, while 7,165 patients were administered pla-
cebo. The majority of patients enrolled in the studies
were male (64 ~ 92.6 %), and the mean age of patients
ranged from 62 to 68 years old. All patients had a long
smoking history, which was estimated to be at least 37
pack-years, and experienced a severe expiratory airflow
obstruction with a mean post-bronchodilator predicted
FEV1 less than 55 %. Details of baseline characteristics
of patients in each enrolled study were shown in
Table 3.
Quality assessment of the 13 enrolled studies showed
that there was no bias in selection, attribution, or
reporting, but 2 studies [16, 22] did not described
methods used in allocation concealment and blinding
of participants and outcome assessments, neither re-
ported whether the outcome data was incomplete or
selective (Fig. 2). No studies excluding for low quality
or dubious decisions were found in the sensitivity ana-
lysis, and no publication bias was detected in the Fun-
nel plot (Fig. 3).
Heterogeneity
We did not find statistical heterogeneity in pre- and
post-bronchodilator FEV1 (Figs. 4 and 5), postbroncho-
dilaotr FVC and FEF25-75 (Fig. 6), TDI (Fig. 7), or inci-
dence of COPD exacerbation (Fig. 9 and 10); whereas
significance statistical heterogeneity was found in post-
bronchodilator FEV6 (I
2 = 58 %, χ2 = 4.77, P = 0.09)
(Fig. 6), SGRQ (I2 = 63 %, χ2 = 1.71, P = 0.07) (Fig. 8), and




The mean difference of pre-bronchodilator FEV1 change
from baseline between treatment with roflumilast and
placebo in 12 weeks, 24 weeks and 52 weeks were
96.75 ml (95 % CI 44.21 ~ 149.29), 65.56 ml (95 % CI
51.84 ~ 79.28), and 45.08 ml (95 % CI 33.64 ~ 56.52),
respectively, which showed that there were significant
differences correspondingly (z = 3.61, P < 0.001; z =
9.37, P < 0.001; and z = 7.72, P < 0.001) as well as in
overall effects (z = 12.47, P <0.001) (Fig. 4). As for
change of post-bronchodilator FEV1 from baseline, we
also found significant differences in 24 weeks (MD
71.63, 95 % CI 57.44 ~ 85.82, z = 9.89, P < 0.001) and
52 weeks (MD 50.41 ml, 95 % CI 40.46 ~ 60.35, z =
9.94, P < 0.001), and in overall effects (MD 57.86 ml,
95 % CI 49.80 ~ 69.51, z = 14.07, P < 0.001) (Fig. 5).
Meanwhile, significant improvement in change of post-
bronchodilator FVC (MD 90.37 ml, 95 % CI 73.95 ~
Fig. 1 Study flow diagram. ACP, American College of Physician; CENTRAL, Cochrane Central Register of Controlled Trials; COPD, chronic obstructive
pulmonary disease; RCT, randomized controlled trial
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Table 1 Details of each enrolled study








Placebo Oral 26 weeks 26 weeks ①
Boszormenyi-Nagy,
2005 [17]






Oral 24 weeks 24 weeks ①
Rabe, 2005 [11] M2-107 COPD with postbronchodilator FEV1%
of 30 ~ 80 %, age ≥ 40 years and a





Placebo Oral 24 weeks 24 weeks ①②③④⑤⑥⑧⑨
Calverley, 2007 [18] NCT00430729
(M2-112)
COPD with postbronchodilator FEV1%
of 50 % or less, age≥ 40 years and a





Placebo Oral 52 weeks 52 weeks ①②③④⑤⑥⑧⑨
Calverley, 2009 [19] NM (M2-124,
M2-125)
COPD with postbronchodilator FEV1%
of 50 % or less, age > 40 years and a





Placebo Oral 52 weeks 52 weeks ①②③⑤⑦⑧⑨
Fabbri,
2009 [13]
M2-127 NCT00313209 COPD with postbronchodilator FEV1%
of 40 ~ 70 %, age > 40 years and a





















COPD with postbronchodilator FEV1%
of 30 ~ 80 %, age ≥ 40 years and a





Placebo Oral 12 weeks 12 weeks ①②③④⑤⑧⑨
aOutcome measures include: ① Change of prebronchodilator FEV1; ② Change of postbronchodilator FEV1; ③ Change of postbronchodilator FVC; ④ Change of postbronchodilator FEV6; ⑤ Change of
postbronchodilator FEF25-75; ⑥ Change of SGRQ; ⑦ Change of TDI; ⑧ Incidence of exacerbation; ⑨ Incidence of adverse events
COPD chronic obstructive pulmonary disease, FEF25-75 forced expiratory flow between 25 and 75 % of the vital capacity, FEV1 forced expiratory volume in one second, FEV6 forced expiratory volume in six seconds FVC










Table 2 Details of each enrolled study






COPD with postbronchodilator FEV1%
of 50 % or less, age≥ 40 years and a
smoking history > 10 pack-year
1173
(567/606)
Roflumilast 500ug Once daily Placebo Oral 52 weeks 52 weeks ①②⑥⑧⑨
Ferguson, 2012
[22]
NCT01443845 Severe-to-very-severe COPD patients
with a history of exacerbations
2300 (1150/1150) Roflumilast 500ug Once daily Placebo Oral 12 months 12 months ⑧
O’Donnell, 2012
[23]
M2-118 COPD with postbronchodilator FEV1%
of 30 ~ 80 %, age ≥ 40 years and a
smoking history ≥ 10 pack-year
250 (127/123) Roflumilast 500ug Once daily Placebo Oral 12 weeks 12 weeks ①②⑤⑦⑧⑨
Zheng, 2014 [24] NCT01313494 COPD with postbronchodilator FEV1%
of 50 % or less, age≥ 40 years and a
smoking history ≥ 10 pack-year





COPD with postbronchodilator FEV1%
of 50 % or less, age≥ 40 years and a
smoking history≥ 20 pack-year
1935 (969/966) Roflumilast 500ug Once daily Placebo Oral 52 weeks 52 weeks ②③⑧⑨
Wells, 2015 [14] NCT01572948 Moderate-to-severe COPD with
age > 40 years and a smoking
history > 10 pack-year
27 (11/16) Roflumilast 500ug Once daily Placebo Oral 30 days 14 weeks (12 weeks
for lung function test)
①②③⑨
aOutcome measures include: ① Change of prebronchodilator FEV1; ② Change of postbronchodilator FEV1; ③ Change of postbronchodilator FVC; ④ Change of postbronchodilator FEV6; ⑤ Change of
postbronchodilator FEF25-75; ⑥ Change of SGRQ; ⑦ Change of TDI; ⑧ Incidence of exacerbation; ⑨ Incidence of adverse events
COPD chronic obstructive pulmonary disease, FEF25-75 forced expiratory flow between 25 and 75 % of the vital capacity, FEV1 forced expiratory volume in one second, FEV6 forced expiratory volume in six seconds, FVC










Table 3 Baseline characteristics of patients in each enrolled trial
Author (year) No.a Age (year, SD)a Sex (Male, %)a BMI (kg/m2, SD)a Smoking (Pack-year, SD)a Post-FEV1/FVC (%, SD)
a Post-FEV1 (L, SD)
a Post-FEV1 (%predicted, SD)
a Post-FVC (L, SD)a
Bredenbroker, 2002 169 NM NM NM NM NM NM NM NM
Boszormenyi-Nagy,
2005
200 NM NM NM NM NM NM NM NM
Rabe, 2005 555 64 (42 ~ 87) 410 (75) 26 (5.0) 41 (20.6) 50 (12) 1.50 (0.48) 54 (13.2) 3.08 (0.85)
Calverley, 2007 760 65 (9.6) 571 (75) 25 (5.0) 42 (22.9) 40.3 (11.2) 1.13 (0.04) 41 (11.0) NM
Calverley, 2009 1537 64 (9) 1150 (75) 25.8 (5.9) 48 (25) 42.3 (11.2) 1.10 (0.4) 36.1 (10.6) NM
Fabbri, 2009 M2-127 466 65 (9) 319 (68) NM 43 (22) 49.8 (9.4) 1.51 (0.4) 54.7 (9.1) NM
M2-128 371 64 (9) 262 (71) NM 43 (22) 52.7 (10.3) 1.55 (0.5) 56.0 (11.6) NM
Lee, 2011 203 68 (41 ~ 91) 188 (92.6) 22.39 (3.7) 42 (22.1) 50.5 (11.8) 1.41 (0.5) 55.1 (16.5) NM
Rennard, 2011
(M2-111)
567 64 (8.7) 387 (68.3) 26.0 (5.7) 50 (28.2) 43.3 (10.1) 1.12 (0.4) 36.8 (10.7) NM
Ferguson, 2012 1150 NM NM NM NM NM NM NM NM
O’Donnell, 2012 127 60 (9) 93 (73.2) 26.4 (5.0) 41 (20) 51 (11) NM 56 (12) NM
Zheng, 2014 313 64.2 (8.76) 283 (90.4) 21.8 (3.42) 37.2 (21.18) 35.78 (9.69) 0.95 (0.35) 36.84 (11.42) NM
Martinez, 2015 969 65 (8.4) 718 (74) 26.5 (5.47) 48 (24.6) 40.2 (10.81) 1.1 (0.33) 35.4 (9.25) NM
Wells, 2015 11 62 (7) 7 (64) NM 47 (26) 53 (12) NM 45 (12) NM
aData reported in all patients receiving vitamin D supplementation










106.78, z = 10.79, P < 0.001), FEV6 (MD 96.55 ml, 95 %
CI 62.77 ~ 130.33, z = 5.60, P < 0.001), and FEF25-75
(MD 21.64 ml/s, 95 % CI 12.53 ~ 30.76, z = 4.65, P <
0.001) were found in roflumilast treatment compared
with placebo (Fig. 6).
Quality of life
Significant improvement of TDI was detected in patients
with roflumilast compared with placebo (MD 0.30, 95 %
CI 0.14 ~ 0.46, z = 3.67, P < 0.001) (Fig. 7); whereas, we did
not find significant difference in SGRQ between the two
treatment groups (MD −1.30, 95 % CI −3.16 ~ 0.56, z =
1.37, P = 0.17) (Fig. 8).
Incidence of COPD exacerbation
Figures 9 and 10 displayed outcomes of incidence of
COPD exacerbation in number per patient per year and in
proportion, respectively, and both showed that roflumilast
significantly decreased COPD exacerbation compared
with placebo (MD −0.22, 95 % CI −0.30 ~ −0.14, z = 5.59,
P < 0.001; RR 0.86, 95 % CI 0.81 ~ 0.91, z = 5.54, P <
0.001). In addition, we also found a significant decrease of
COPD exacerbation in patients with roflumilast in
24 weeks (MD −0.42, 95 % CI −0.64 ~ −0.19, z = 3.68, P <
0.001; RR 0.80, 95 % CI 0.71 ~ 0.90, z = 3.62, P < 0.001)
and 52 weeks (MD −0.19, 95 % CI −0.28 ~ −0.11, z = 4.59,
P < 0.001; RR 0.88, 95 % CI 0.83 ~ 0.94, z = 4.18, P <
0.001), but no significance was reported in 12 weeks (RR
0.74, 95 % CI 0.38 ~ 1.45, z = 0.87, P = 0.38).
Incidence of adverse events
A great variety of adverse events were detected in pa-
tients with roflumilast, among which diarrhea (2.7–
12.1 %), weight loss (1.0–12 %), upper respiratory tract
infection (2–13.3 %), nasopharyngitis (3.4–8 %), nausea
(1.0–6 %), and headache (1.3–4 %) were mainly reported.
Discontinuations due to adverse events were more com-
mon in patients with roflumilast (5 ~ 14 %) than placebo
(2.9 ~ 11 %), however, the incidence of serious adverse
events resembled between patients with roflumilast (7 ~
19 %) and placebo (10 ~ 22 %).
Pooled analysis of 10 studies showed that significantly
higher incidence of adverse events were found in patients
with roflumilast compared with placebo in 12 weeks (RR
1.51, 95 % CI 1.26 ~ 1.80, z = 4.47, P < 0.001) and 24 weeks
(RR 1.76, 95 % CI 1.22 ~ 2.52, z = 3.06, P = 0.002), as well
as in overall effects (RR 1.31, 95 % CI 1.16 ~ 1.47, z = 4.32,
P < 0.001). However, such a significant difference disap-
peared in 52 weeks (RR 1.06, 95 % CI 1.00 ~ 1.11, z = 1.99,
P = 0.05) (Fig. 11).
Discussion
In our meta-analysis, we found that roflumilast could
significantly improve lung functions, including pre- and
Fig. 3 Funnel plot. FEV1, forced expiratory volume in one second
Fig. 2 Risk of bias summary
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post-bronchodilator FEV1, FVC, FEV6 and FEF25-75, al-
leviate dyspnea symptoms (TDI), and decrease inci-
dence of acute exacerbation, but could not improve
quality of life (SGRQ) or decrease early acute exacerba-
tion onset, even with a significant increase of risk of ad-
verse events.
Persistent airflow limitation is the hallmark of COPD,
which is also used to evaluate the severity and treatment
responses by GOLD guideline [1]. FEV1 is the most com-
mon spirometric parameter to assess airflow limitation,
and the post-bronchodilator FEV1 independently divided
patients with COPD into 4 stages of severity, and classified
Fig. 5 Effects of roflumilast vs. placebo on postbronchodilator FEV1. CI, confidence interval; FEV1, forced expiratory volume in one second; SD,
standard derivation
Fig. 4 Effects of roflumilast vs. placebo on prebronchodilator FEV1. CI, confidence interval; FEV1, forced expiratory volume in one second; SD,
standard derivation
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them into 4 groups with symptoms and acute exacerba-
tions. Therefore, FEV1 improvement is usually rendered as
an important factor to identify the treatment efficacy of a
new drug for COPD. Previous meta-analyses have reported
that roflumilast significantly improved lung function
through pre-bronchodilator FEV1 compared with pla-
cebo, but they did not evaluate the post-bronchodilator
FEV1 nor consider the onset time of roflumilast in im-
proving FEV1 [12, 26, 27]. Our study not only
confirmed the effect of roflumilast on improving both pre-
and post-bronchodilator FEV1, post-bronchodilator FEV6
and FEF25-75, but also further demonstrated that roflumi-
last could improve FEV1 as early as 12 weeks and the
improvement effect lasted for as long as 52 weeks
afterward, which we think has important clinical in-
sights because it can facilitate physicians to set up the
optimal follow-up plan and determine the administra-
tion duration.
It is well known that FVC is a volumetric parameter,
which represents lung volume change and is rarely
used to assess treatment responses in patients with
COPD. Recent years, however, Tashkin and his col-
leagues conducted a cohort study of 5,756 patients
with moderate-to-severe COPD to examine acute bron-
chodilator responsiveness patterns in theses patients, and
they found that mean improvements from baseline were
229 ml in FEV1 and 407 ml in FVC, and approximately
49 % of patients with very severe COPD showed a volume
response rather than a flow response to the bronchodila-
tors [28], which also revealed the potential value of FVC
alteration in evaluating treatment responses in patients
with severe airflow limitation and failed to exhibit the
requisite threshold increase in FEV1. In our study, 6 stud-
ies reported the change of FVC from baseline and the final
pooled analysis resulted in greater improvement of FVC
in patients with roflumilast than placebo. However, we
could not compare the mean change of FVC and FEV1 or
analyze the proportion of patients who responded to FVC
and FEV1 due to the insufficient data reported. Therefore,
future studies focusing on these issues were warranted.
Chronic and progressive dyspnea is one of the typical
symptoms in patients with COPD, and is a major cause
Fig. 7 Effect of roflumilast vs. placebo on TDI. CI, confidence interval; SD, standard derivation; TDI, transition dyspnea index
Fig. 6 Effects of roflumilast vs. placebo on post-bronchodilator FVC, FEV6 and FEF25-75. CI, confidence interval; FEF25-75, forced expiratory flow
between 25 and 75 % of the vital capacity; FEV6, force expiratory volume in six seconds; FVC, forced vital capacity; SD, standard derivation
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of disability and impaired quality of life [1]. In our
pooled meta-analysis, we found a significant improve-
ment of TDI but without decreasing SGRQ scores in pa-
tients with roflumilast compared with placebo. That is,
roflumilast could relieve the symptom of dyspnea, but
could not attenuate other symptoms including but not
limited to cough, sputum, activity endurance, and daily
life. As we know, TDI is an evaluative instrument to
measure breathlessness related to activities of daily liv-
ing, and a large of RCTs have demonstrated reliability
and accuracy in the characteristics of TDI [29]; while
SGRQ is a widely used questionnaire with documented
comprehensive measures, and it is recommended that
regular treatment for symptoms should be considered if
a COPD patient with a symptom score equivalent to
SGRQ score ≥ 25 [30–32]. Thus, the different outcomes
in the effects of roflumilast on TDI and SGRQ may due
to the different content and aspects in each scoring sys-
tem. However, interpretation of our results should be
cautious because of the potential heterogeneity in
SGRQ, and the difference of corresponding parts about
dyspnea in SGRQ still remains unknown.
COPD exacerbation is an acute event, which can lead
to the decline of lung functions and even be fatal to pa-
tients [1]. The three meta-analyses mentioned previously
also demonstrated the significant decrease of acute ex-
acerbation rate in treatment with roflumilast, but they
again did not take the different time points into account
when evaluated the effect of roflumilast on affecting
incidence of acute exacerbation [12, 26, 27]. Our study
illustrated that although roflumilast could significantly
reduce the incidence of acute exacerbation, but we did
not find such an effect before 24 weeks. Therefore, the
improvement of lung function may be earlier than de-
crease of acute exacerbation, and a minimal treatment
duration of 24 weeks might be optimal to achieve im-
provement of both lung functions and acute exacerba-
tion, which was also explained by a recent RCT with
negative effects in FEV1 and acute exacerbation due to
limited follow-up [14]. Nevertheless, we should notice
the limited studies with relatively small samples and the
various conditions conducted in different studies with
different lengths, and further studies in evaluating acute
exacerbation in 12 weeks are needed before a precise
conclusion can be drawn.
It has long been recognized that weight loss, malnutri-
tion and skeletal muscle dysfunction are common co-
morbidities in patients with COPD especially in later
stage [33]. Based on the presently available studies, the
mostly reported adverse events are diarrhea and weight
loss. Our meta-analysis indeed showed a significant in-
crease of adverse event in patients with roflumilast,
which further demonstrated the conclusions by Yan and
Chong [12, 27], but went contrary to the findings of Oba
[26]. However, Rabe and his colleagues also perceived
that most adverse events (>90 %) resolved or relieved
during the course of the study [11]. Meanwhile, in our
study, we also found that the incidence of adverse events
Fig. 9 Effect of roflumilast vs. placebo on incidence of COPD exacerbation (number per patient per year). CI, confidence interval; COPD, chronic
obstructive pulmonary disease; SD, standard derivation
Fig. 8 Effect of roflumilast vs. placebo on SGRQ. CI, confidence interval; SD, standard derivation; SGRQ, St George’s Respiratory Questionnaire
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Fig. 10 Effect of roflumilast vs. placebo on incidence of COPD exacerbation (patients per total). CI, confidence interval; COPD, chronic obstructive
pulmonary disease; M.-H., Mantel-Haenszel
Fig. 11 Effect of roflumilast vs. placebo on incidence of adverse events. CI, confidence interval; M.-H., Mantel-Haenszel
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between roflumilast and placebo was similar in 52 weeks
even though the P value was on the borderline. As a re-
sult, administration of roflumilast should be cautious
with consideration of the treatment benefits and detri-
ments in patients with COPD comorbidities.
Limitations for our meta-analysis are as follows: First,
the baseline demographics of patients and extent of air-
flow limitation in COPD were not identical among the
enrolled trials, which may lead to selection biases. Sec-
ond, potential heterogeneities existed in some outcomes
such as post-bronchodilator FEV6, SGRQ and incidence
of adverse events, which may cause potential confusions
to our results and conclusions. Third, the number of
studies and patients for pre- and post-FEV1 varied in dif-
ferent follow-up groups, especially in 12 weeks, which
may also result in inaccurate conclusions. Finally, sub-
group analysis of FVC by follow-up time points and
comparison of improvement degrees and proportions
between FVC and FEV1 could not be achieved due to
limited data and studies.
Conclusions
Roflumilast can be considered as an alternative therapy
in selective patients with moderate-to-severe COPD due
to the effect of lung function improvement, dyspnea alle-
viation and acute exacerbation decrease but increase of
risk of adverse events. More large studies are needed, par-
ticularly with different follow-up and treatment duration,
to further determine the role of roflumilast, including
cost-effectiveness and time-to-survive, in patients with
moderate-to-severe COPD.
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